Gene-expression tester XDx marks the spot with an $86M IPO bid

October 27, 2007 | David P. Hamilton | Comments | |

See our story on this Brisbane, Calif., genomic-diagnostic firm at VentureBeat Life Sciences.

Next Story: IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings
Previous Story: Facebook deal still hasn’t happened

Bookmark and Share

Photo of David P. Hamilton

About the Author, David P. Hamilton

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.